(June 13, 2023, 3:10 PM EDT) -- WASHINGTON, D.C. — The three major insulin makers and three major pharmacy benefit managers (PBMs) have told the Judicial Panel on Multidistrict Litigation that there is no need to centralize federal court insulin pricing antitrust cases brought by five states into an MDL but suggest that if the motion is granted, the cases be transferred to the U.S. District Court for the District of Kansas....